格隆汇12月30日丨华兰疫苗(301207.SZ)在互动平台表示，公司流感疫苗曾经出口至乌克兰、摩尔多瓦 等国家，暂未出口至日本，目前主要供应国内市场。 ...

键凯科技12月29日大宗交易平台出现一笔成交，成交量2.70万股，成交金额203.53万元，大宗交易成交 价为75.38元，相对今日收盘价折价8.63%。该笔交易的买方营业部为机构专用，卖方营业部为平安证券 股份有限公司泉州滨海街证券营业部。 进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为2961.40万元。 证券时报·数据宝统计显示，键凯科技今日收盘价为82.50元，上涨0.66%，日换手率为0.42%，成交额为 2106.41万元，全天主力资金净流出172.54万元，近5日该股累计下跌0.12%，近5日资金合计净流出 225.23万元。 两融数据显示，该股最新融资余额为1.72亿元，近5日增加203.82万元，增幅为1.20%。 据天眼查APP显示，北京键凯科技股份有限公司成立于2001年10月09日，注册资本6065.07万人民币。 （数据宝） 12月29日键凯科技大宗交易一览 （文章来源：证券时报网） | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） ...

Core Viewpoint - Anke Bio (300009) reported a significant increase in sales revenue for its injectable trastuzumab "Ansaiting," projecting a year-on-year growth of 298% in the first half of 2025 [1] Group 1 - The company anticipates a substantial rise in sales revenue for its product, indicating strong market demand and potential growth opportunities [1]

证券日报网讯12月29日，中牧股份（600195）在互动平台回答投资者提问时表示，公司是高致病性禽流 感等重大动物疫病疫苗的定点生产企业，拥有完备的生产线，禽流感疫苗种类丰富，产品出口多国。同 时，公司将持续关注禽流感疫病的流行趋势，适时调整生产供应计划，为禽类养殖企业提供安全、有效 的禽流感疫苗产品。 ...

Group 1 - The company, Meihua Biological (600873.SH), announced a share buyback plan intended for future employee stock ownership plans or equity incentives [1] - The total amount for the buyback will not be less than 35 million RMB and not exceed 50 million RMB [1] - The buyback price will not exceed 15 RMB per share [1]

每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 （记者 王晓波） 每经AI快讯，康泰生物（SZ 300601，收盘价：14.98元）发布公告称，2025年12月25日，康泰生物接受 华安基金等投资者调研，公司投资者关系总监吴华参与接待，并回答了投资者提出的问题。 2024年1至12月份，康泰生物的营业收入构成为：生物制品占比98.31%，其他业务收入占比1.69%。 截至发稿，康泰生物市值为167亿元。 ...

Group 1: Vaccine Development Progress - The five-component vaccine is currently in Phase III clinical trials, making it the fastest progressing domestic five-component vaccine in China, aiming to break the import monopoly [1] - The recombinant hepatitis B vaccine for chronic hepatitis B patients has received clinical trial approval, targeting a population of approximately 75 million chronic HBV carriers in China [2] - The company is also developing a Klebsiella pneumoniae vaccine to address antibiotic-resistant bacteria, which is a significant global public health challenge [3] Group 2: Market Potential and Growth - The global chronic hepatitis B infection rate is approximately 254 million, with a prevalence rate of 5% to 7% in China, indicating a substantial unmet clinical need [2] - The hepatitis B virus drug market in China is projected to exceed 70 billion yuan by 2030, with an annual compound growth rate of 18% from 2019 to 2030 [2] - The adult vaccination market in China remains underdeveloped compared to developed countries, presenting significant growth opportunities as public awareness increases [3] Group 3: Research and Development Investment - In the first half of 2025, the company invested 334 million yuan in R&D, accounting for 23.96% of its revenue, a 41.52% increase from the same period in 2024 [4] - The company is advancing multiple vaccine candidates, including the four-valent influenza vaccine and the five-component vaccine, with several in various clinical trial phases [5] Group 4: International Expansion - The company is expanding its international presence through partnerships in over 20 countries, focusing on product registration and commercialization [6] - In the first three quarters of 2025, overseas revenue reached 41.9 million yuan, a 324.27% increase year-on-year [7] Group 5: Future Development Strategy - The company plans to enhance its market presence through "internal innovation + external expansion," focusing on core pipeline advantages and optimizing sales networks [8] - Continuous R&D investment will drive the development of multi-component, adult, innovative, and therapeutic vaccines, aiming to build a competitive product matrix [9] Group 6: Shareholder Returns - In June 2025, the company distributed cash dividends amounting to 101 million yuan, representing 49.85% of the net profit attributable to shareholders for 2024 [9] - Since its listing in 2017, the company has distributed a total of 1.885 billion yuan in cash dividends, accounting for 44.66% of the total net profit attributable to shareholders [9]

每经AI快讯，赛分科技（SH 688758，收盘价：17.93元）12月29日晚间发布公告称，公司限售股份约 2.56亿股将于2026年1月12日解禁并上市流通，占公司总股本比例为61.4%。 每经头条（nbdtoutiao）——直击茅台经销商大会：2000多人周末齐聚！重大变革公布：涉及茅台酒价 格、分销等，董事长陈华：经销商不能再"躺着赚钱" （记者 曾健辉） 2024年1至12月份，赛分科技的营业收入构成为：药物分析占比40.2%，抗体药物占比20.85%，胰岛素/ 多肽/GLP-1占比18.18%，重组蛋白占比13.73%，其他占比6.6%。 截至发稿，赛分科技市值为75亿元。 ...

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - The report emphasizes the importance of systematically researching next-generation innovative drugs for resistant hypertension (rHTN), highlighting that multiple new mechanism antihypertensive drugs will read out data and/or achieve clinical progress by 2025 [2] - Key catalysts include upcoming Phase 3 clinical studies focusing on cardiovascular and renal endpoints, which are expected to provide significant data in the coming years [2] - The report suggests paying attention to domestic companies involved in relevant target areas [2] Summary by Sections 01 Current Status and Unmet Needs in Hypertension Treatment - Hypertension is a prevalent cardiovascular disease, with approximately 90%-95% of patients suffering from primary hypertension, driven by factors such as salt sensitivity and obesity [3] - In the US, the prevalence of hypertension is around 48%, corresponding to approximately 120 million people, with about 60 million receiving antihypertensive treatment [3] - In China, the prevalence among adults aged 18 and older was 27.5% in 2018, with awareness, treatment, and control rates at 51.6%, 45.8%, and 16.8%, respectively [3] 02 Next-Generation Drug Focus on AGT and ASI - The report discusses the focus on AGT (Angiotensinogen) and ASI (Angiotensin II receptor blockers) in the development of next-generation antihypertensive drugs [3] - AGT-targeting drugs, particularly siRNA and ASO therapies, are highlighted as promising avenues for reducing blood pressure effectively [27] 03 Investment Recommendations - The report suggests that the market for resistant hypertension treatments is highly structured, with a focus on balancing efficacy and safety in drug development [16] - It emphasizes the need for drugs that can manage long-term adherence and safety, particularly for patients with comorbidities such as CKD and HF [19]

Group 1 - The first six-valent rotavirus vaccine in China, covering six serotypes, completed its first dose administration in Wuhan on December 26 [1] - Rotavirus is a significant pathogen causing acute gastroenteritis in infants and young children, posing a continuous health challenge for children under five in China [1] - The World Health Organization identifies vaccination as the most economical and effective public health intervention to reduce the burden of rotavirus-related diseases, recommending it as a key vaccine for national immunization programs [1] Group 2 - The newly developed vaccine by China National Pharmaceutical Group's Wuhan Institute of Biological Products addresses both traditional and emerging rotavirus serotypes, reflecting recent monitoring trends [1] - Approved for market on September 12, the vaccine is classified as a Category 1 new drug for preventive biological products in China and is administered orally to infants aged 6 weeks to 36 weeks [1] - The nationwide vaccination campaign will be gradually initiated, with efforts to enhance vaccination service management, monitoring, and public health education [1][2]